These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

630 related articles for article (PubMed ID: 35651605)

  • 1. Advances in Nanotechnology-Based Immunotherapy for Glioblastoma.
    Tang L; Zhang M; Liu C
    Front Immunol; 2022; 13():882257. PubMed ID: 35651605
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The CNS and the Brain Tumor Microenvironment: Implications for Glioblastoma Immunotherapy.
    Desland FA; Hormigo A
    Int J Mol Sci; 2020 Oct; 21(19):. PubMed ID: 33027976
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune Escape in Glioblastoma Multiforme and the Adaptation of Immunotherapies for Treatment.
    Pearson JRD; Cuzzubbo S; McArthur S; Durrant LG; Adhikaree J; Tinsley CJ; Pockley AG; McArdle SEB
    Front Immunol; 2020; 11():582106. PubMed ID: 33178210
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Present and Future of Immunotherapy in Patients With Glioblastoma: Limitations and Opportunities.
    Maccari M; Baek C; Caccese M; Mandruzzato S; Fiorentino A; Internò V; Bosio A; Cerretti G; Padovan M; Idbaih A; Lombardi G
    Oncologist; 2024 Apr; 29(4):289-302. PubMed ID: 38048782
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hypoxia within the glioblastoma tumor microenvironment: a master saboteur of novel treatments.
    Feldman L
    Front Immunol; 2024; 15():1384249. PubMed ID: 38994360
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multiple Synergistic Effects of the Microglia Membrane-Bionic Nanoplatform on Mediate Tumor Microenvironment Remodeling to Amplify Glioblastoma Immunotherapy.
    Fan Q; Kuang L; Wang B; Yin Y; Dong Z; Tian N; Wang J; Yin T; Wang Y
    ACS Nano; 2024 Jun; 18(22):14469-14486. PubMed ID: 38770948
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Extrinsic factors associated with the response to immunotherapy in glioblastoma.
    Bi H; Zhang C
    Cancer Lett; 2021 Jul; 511():47-55. PubMed ID: 33933551
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination immunotherapy strategies for glioblastoma.
    Chan HY; Choi J; Jackson C; Lim M
    J Neurooncol; 2021 Feb; 151(3):375-391. PubMed ID: 33611705
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Translational landscape of glioblastoma immunotherapy for physicians: guiding clinical practice with basic scientific evidence.
    Kreatsoulas D; Bolyard C; Wu BX; Cam H; Giglio P; Li Z
    J Hematol Oncol; 2022 Jun; 15(1):80. PubMed ID: 35690784
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Applications of nanotechnology in remodeling the tumour microenvironment for glioblastoma treatment.
    Mu Y; Zhang Z; Zhou H; Ma L; Wang DA
    Biomater Sci; 2024 Aug; 12(16):4045-4064. PubMed ID: 38993162
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combinatorial approaches to effective therapy in glioblastoma (GBM): Current status and what the future holds.
    Asija S; Chatterjee A; Yadav S; Chekuri G; Karulkar A; Jaiswal AK; Goda JS; Purwar R
    Int Rev Immunol; 2022; 41(6):582-605. PubMed ID: 35938932
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacological targeting of the tumor-immune symbiosis in glioblastoma.
    Pang L; Khan F; Dunterman M; Chen P
    Trends Pharmacol Sci; 2022 Aug; 43(8):686-700. PubMed ID: 35534356
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phenotypic plasticity of myeloid cells in glioblastoma development, progression, and therapeutics.
    Ye Z; Ai X; Zhao L; Fei F; Wang P; Zhou S
    Oncogene; 2021 Oct; 40(42):6059-6070. PubMed ID: 34556813
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Different T-cell subsets in glioblastoma multiforme and targeted immunotherapy.
    Wang H; Zhou H; Xu J; Lu Y; Ji X; Yao Y; Chao H; Zhang J; Zhang X; Yao S; Wu Y; Wan J
    Cancer Lett; 2021 Jan; 496():134-143. PubMed ID: 33022290
    [TBL] [Abstract][Full Text] [Related]  

  • 15. GBM immunotherapy: Exploring molecular and clinical frontiers.
    Ghosh MK; Kumar S; Begam S; Ghosh S; Basu M
    Life Sci; 2024 Nov; 356():123018. PubMed ID: 39214286
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recruiting T-Cells toward the Brain for Enhanced Glioblastoma Immunotherapeutic Efficacy by Co-Delivery of Cytokines and Immune Checkpoint Antibodies with Macrophage-Membrane-Camouflaged Nanovesicles.
    Xu X; Zhang Z; Du J; Xue Y; Chen X; Zhang J; Yang X; Chang D; Xie J; Ju S
    Adv Mater; 2023 Jun; 35(25):e2209785. PubMed ID: 37101060
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunotherapy for glioblastoma: the promise of combination strategies.
    Bausart M; Préat V; Malfanti A
    J Exp Clin Cancer Res; 2022 Jan; 41(1):35. PubMed ID: 35078492
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Natural Killer Cell-Based Immunotherapy against Glioblastoma.
    Morimoto T; Nakazawa T; Maeoka R; Nakagawa I; Tsujimura T; Matsuda R
    Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768432
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emerging therapies for glioblastoma: current state and future directions.
    Rong L; Li N; Zhang Z
    J Exp Clin Cancer Res; 2022 Apr; 41(1):142. PubMed ID: 35428347
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune checkpoint pathways in glioblastoma: a diverse and evolving landscape.
    Inocencio JF; Mitrasinovic S; Asad M; Parney IF; Zang X; Himes BT
    Front Immunol; 2024; 15():1424396. PubMed ID: 39346924
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.